NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

HEPA

Hepion Pharmaceuticals Inc

Apr 21 • 04:00PM ET

0.2700

Dollar change -0.0521
Percentage change -16.18	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX BIIB MDGL EXEL IONS AKRO NBIX ARWR LLY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-109.30	Insider Own	0.48%	Shs Outstand	10.98M	Perf Week	-36.02%
Market Cap	2.97M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.92M	Perf Month	-67.43%
Income	-13.19M	PEG	-	EPS next Q	-	Inst Own	0.28%	Short Float	1.83%	Perf Quarter	-98.85%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	310.25%	Short Ratio	0.05	Perf Half Y	-99.10%
Book/sh	-25.57	P/B	-	EPS next Y	-	ROA	-133.45%	Short Interest	0.20M	Perf Year	-99.75%
Cash/sh	0.04	P/C	7.24	EPS next 5Y	-	ROE	-487.03%	52W Range	0.31 - 110.50	Perf YTD	-98.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	55.44%	ROI	-	52W High	-99.76%	Beta	1.89
Dividend TTM	-	Quick Ratio	0.51	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-11.48%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	0.51	EPS Y/Y TTM	82.26%	Oper. Margin	-	RSI (14)	20.28	Volatility	12.25% 28.49%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	1100.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	90.82%	Payout	-	Rel Volume	0.29	Prev Close	0.32
Sales Surprise	-	EPS Surprise	-17.54%	Sales Q/Q	-	Earnings	-	Avg Volume	4.12M	Price	0.27
SMA20	-42.72%	SMA50	-92.49%	SMA200	-98.92%	Trades		Volume	1,177,510	Change	-16.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-20	Resumed	ROTH Capital	Buy	$14

Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -39.15%
08:30AM	Hepion Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire)
Jan-22-25 08:00AM	Hepion Pharmaceuticals Announces $9.0 Million Public Offering (GlobeNewswire) -58.05%
Dec-11-24 08:00AM	Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. (GlobeNewswire) -7.15%
Dec-05-24 08:30AM	Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group (GlobeNewswire)
08:00AM	Loading…
Dec-02-24 08:00AM	Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B (GlobeNewswire) -5.69%
Nov-11-24 08:00AM	Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger (GlobeNewswire) +7.64%
Sep-04-24 09:25AM	Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger (GlobeNewswire)
Jul-22-24 08:00AM	Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement (GlobeNewswire) -17.65%
May-21-24 09:52PM	HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Apr-22-24 08:56AM	Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today? (InvestorPlace) -29.85%
Apr-19-24 04:30PM	Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial (GlobeNewswire)
Apr-16-24 11:52PM	HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) -6.42%
Mar-06-24 08:30AM	Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell (GlobeNewswire) -11.92%
Feb-16-24 08:00AM	Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds (GlobeNewswire) -5.19%
05:15PM	Loading…
Jan-03-24 05:15PM	Hepion Pharmaceuticals to Present at NASH-TAG 2024 (GlobeNewswire)
Dec-07-23 08:00AM	Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes (GlobeNewswire) -5.56%
Nov-28-23 04:15PM	Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit (GlobeNewswire)
Nov-13-23 04:05PM	Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease (GlobeNewswire) +13.82% -15.33%
Nov-10-23 08:50AM	Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat (GlobeNewswire)
Oct-25-23 08:30AM	Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model (GlobeNewswire)
Sep-29-23 08:00AM	Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Sep-21-23 04:05PM	Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference (GlobeNewswire) -7.89%
08:00AM	New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals Rencofilstat in Cancer Screening Program (GlobeNewswire)
Sep-19-23 09:00AM	Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer (GlobeNewswire)
Sep-18-23 11:01AM	Insider Buying: Robert Foster Acquires 1,600 Shares of Hepion Pharmaceuticals Inc (GuruFocus.com) +6.10%
Sep-14-23 08:45AM	Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Sep-06-23 04:30PM	Hepion Pharmaceuticals Announces Management Changes (GlobeNewswire) -10.71%
Jun-15-23 04:45PM	Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress 2023 (GlobeNewswire)
08:22AM	Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ASCEND-NASH Trial of Rencofilstat (GlobeNewswire)
04:45PM	Loading…
May-24-23 04:45PM	Hepion Pharmaceuticals to Highlight AI-POWR at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences (GlobeNewswire) -12.20% -17.30%
May-22-23 07:00AM	Hepion Pharmaceuticals Phase 2 ALTITUDE-NASH Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers (GlobeNewswire) +118.40%
May-19-23 04:05PM	Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ALTITUDE-NASH Liver Function Trial of Rencofilstat (GlobeNewswire)
May-10-23 11:15AM	Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split (GlobeNewswire) -17.32%
Apr-17-23 04:15PM	Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023 (GlobeNewswire)
Mar-30-23 08:45AM	Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs (GlobeNewswire) +8.79%
Mar-16-23 04:10PM	Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development (GlobeNewswire)
Mar-02-23 04:15PM	Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress (GlobeNewswire) +9.31%
09:15AM	EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepions Patent Portfolio (GlobeNewswire)
Feb-09-23 04:15PM	Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023 (GlobeNewswire) -5.74% +7.04%
Jan-18-23 09:15AM	Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies (GlobeNewswire) -24.60%
Jan-10-23 04:15PM	Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors (GlobeNewswire) +35.42%
Jan-09-23 08:00AM	Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding (GlobeNewswire)
Jan-05-23 04:15PM	Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023 (GlobeNewswire) +25.40%
Dec-05-22 04:30PM	Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements (GlobeNewswire)
09:00AM	Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ALTITUDE-NASH Liver Function Trial (GlobeNewswire)
Nov-07-22 08:00AM	Hepion Pharmaceuticals to Present Rencofilstats Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit (GlobeNewswire) -5.92%
Nov-04-22 08:30AM	Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock (GlobeNewswire) -23.98%
Nov-02-22 08:00AM	Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-26-22 08:00AM	Hepion Pharmaceuticals Announces Publication of Phase 2a AMBITION Clinical Trial Results (GlobeNewswire) +8.68%
Oct-20-22 04:30PM	Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat (GlobeNewswire)
Oct-19-22 08:00AM	Hepion Pharmaceuticals to Participate in the ThinkEquity Conference (GlobeNewswire)
Sep-26-22 05:00PM	Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire) -6.06% +5.63%
Sep-14-22 08:00AM	Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceuticals Rencofilstat to Treat Alcohol-Related Liver Disease (GlobeNewswire)
Sep-12-22 08:00AM	Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ALTITUDE-NASH Liver Function Trial (GlobeNewswire)
Sep-08-22 08:00AM	Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-31-22 08:00AM	Hepion Pharmaceuticals Announces Initiation of Phase 2b ASCEND-NASH Trial (GlobeNewswire)
Jul-22-22 04:15PM	Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jul-04-22 10:23AM	We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate (Simply Wall St.)
Jun-28-22 08:30AM	Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati (GlobeNewswire)
Jun-24-22 04:15PM	Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jun-20-22 08:00AM	Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma (GlobeNewswire)
Jun-15-22 08:00AM	Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress 2022 (GlobeNewswire)
Jun-14-22 08:00AM	Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer (GlobeNewswire)
May-31-22 04:30PM	Hepion Pharmaceuticals Urges Shareholders to Vote FOR All Proposals Ahead of its Upcoming Annual Meeting (GlobeNewswire)
May-27-22 08:54AM	CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc. (GlobeNewswire) +6.32%
08:00AM	Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress (GlobeNewswire)
May-03-22 08:00AM	Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial (GlobeNewswire)
Mar-07-22 08:00AM	Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference (GlobeNewswire) -7.32%
Feb-15-22 08:00AM	Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Companys Strategic Medical Affairs in Asia (GlobeNewswire)
Feb-14-22 08:00AM	Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference (GlobeNewswire)
Jan-26-22 08:00AM	Hepion Pharmaceuticals Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study (GlobeNewswire)
Jan-12-22 08:00AM	Hepion Pharmaceuticals Announces Death of Director, Thomas Adams (GlobeNewswire)
Jan-06-22 04:15PM	Hepion Pharmaceuticals Announces USAN Selection of Rencofilstat as Nonproprietary Name for CRV431 (GlobeNewswire)
Jan-05-22 04:30PM	Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference (GlobeNewswire)
08:30AM	Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference (GlobeNewswire)
Dec-21-21 08:00AM	Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer (GlobeNewswire)
Nov-30-21 08:00AM	Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH (GlobeNewswire)
Nov-16-21 08:45AM	Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study (GlobeNewswire)
Nov-10-21 08:00AM	Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 (GlobeNewswire)
07:55AM	Anti-Cancer Mechanism of Hepion Pharmaceuticals CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 (GlobeNewswire)
Nov-04-21 08:00AM	Hepion Pharmaceuticals Presents at the EquitiesIQ Q4 2021 Investor Forum (GlobeNewswire)
Nov-02-21 08:00AM	Hepion Pharmaceuticals to Present at the EquitiesIQ Q4 2021 Investor Forum (GlobeNewswire)
Oct-07-21 08:00AM	Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference (GlobeNewswire)
Sep-29-21 09:00AM	All Endpoints Met in Hepion Pharmaceuticals Drug-Drug Interaction Study with CRV431 (GlobeNewswire)
Sep-13-21 08:00AM	Additional Data from Hepion Pharmaceuticals Phase 2a AMBITION Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ASCEND-NASH Clinical Program (GlobeNewswire)
Sep-10-21 04:05PM	Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a AMBITION Clinical Trial of CRV431 in NASH (GlobeNewswire)
Aug-15-21 05:50AM	Is Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Popular Amongst Institutions? (Simply Wall St.)
Jul-23-21 04:40PM	Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders (GlobeNewswire)
Jul-13-21 08:00AM	Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a AMBITION NASH Trial; All Primary Endpoints Achieved (GlobeNewswire) -15.27%
Jun-25-21 04:30PM	Hepion Pharmaceuticals Announces Adjournment of Annual Meeting (GlobeNewswire)
Jun-09-21 07:45AM	Hepion Pharmaceuticals to be Added to the Russell Microcap® Index (GlobeNewswire)
May-16-21 05:10AM	Hepion Pharmaceuticals (NASDAQ:HEPA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-06-21 07:45AM	Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH (GlobeNewswire)
Apr-29-21 09:50AM	Hepion Pharmaceuticals Presents Machine Learning Learn and Confirm Modeling Strategy at 4th Global NASH Congress (GlobeNewswire)
Mar-23-21 07:15AM	DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceuticals Lead Drug, CRV431 (GlobeNewswire)
Mar-22-21 04:30PM	Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference (GlobeNewswire)
Mar-11-21 07:30AM	Hepion Pharmaceuticals to Present on CRV431 and AI-POWR at NASH-TAG 2021 (ACCESSWIRE) +11.48%
Feb-18-21 04:30PM	Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering (ACCESSWIRE)
Feb-16-21 06:45AM	Hepion Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -25.25%

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HEPA

Hepion Pharmaceuticals Inc

Upgrade your FINVIZ experience